イニパリブ
↑ “International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65”. World Health Organization. p. 68 (2011年). 2016年12月20日閲覧。
↑ “Development of PARP inhibitors: an unfinished story”. Oncology (Williston Park, N.Y.) 24 (1): 66, 68. (January 2010). PMID 20187324.
↑ “Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor”. Clinical Cancer Research 18 (2): 510–23. (January 2012). doi:10.1158/1078-0432.CCR-11-1973. PMID 22128301.
↑ “Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro”.
↑ 臨床試験番号 NCT00938652 研究名 "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer" - ClinicalTrials.gov 2009 to 2012, Primary completion date June 2011
↑ 臨床試験番号 NCT01082549 研究名 "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer (ECLIPSE)" - ClinicalTrials.gov 2010 to 2014, PCD 2012
↑ “Sanofi's new drug BSI 201 offers to treat the toughest breast cancer”. (2009年6月3日). オリジナルの2009年10月18日時点におけるアーカイブ。. https://web.archive.org/web/20091018233201/http://www.dancewithshadows.